(Reuters) - The drop comes just over a month after the stock more than doubled in a single session when a U.S. Food and Drug Administration advisory panel recommended approval.
Dendreon said the FDA had issued a so-called "approvable letter" for Provenge but wanted additional clinical data in support of its efficacy claim. It also requested more information about chemistry, manufacturing and controls.
Read more at Reuters.com Hot Stocks News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment